Investors: Corporate Profile
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
In the United States, our product is called HEPZATO KIT™ (melphalan) for Injection/Hepatic Delivery System (HDS).
In Europe, our commercial, medical device product is called CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP).
For more information about our treatments, please visit:
Delcath Systems, Inc. (NASDAQ-DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.